<!DOCTYPE html>
<html lang="en">
<head>
<script async src="https://www.googletagmanager.com/gtag/js?id=G-6H85DH0R8S"></script>
<script>
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());
  gtag('config', 'G-6H85DH0R8S');
</script>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>GLP-1 Medications Compared: Ozempic vs Wegovy vs Mounjaro vs Zepbound ‚Äî glp1.md</title>
    <meta name="description" content="Compare GLP-1 receptor agonists head-to-head: weight loss results, side effects, cost, and which might work best for you.">
    <meta name="author" content="thrive.md Editorial Team">
    <link rel="canonical" href="https://glp1.md/blog/glp1-medications-compared/">
    <meta property="og:type" content="article">
    <meta property="og:url" content="https://glp1.md/blog/glp1-medications-compared/">
    <meta property="og:title" content="GLP-1 Medications Compared: Ozempic vs Wegovy vs Mounjaro vs Zepbound ‚Äî glp1.md">
    <meta property="og:description" content="Compare GLP-1 receptor agonists head-to-head: weight loss results, side effects, cost, and which might work best for you.">
    <meta property="og:site_name" content="glp1.md">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:title" content="GLP-1 Medications Compared: Ozempic vs Wegovy vs Mounjaro vs Zepbound ‚Äî glp1.md">
    <meta name="twitter:description" content="Compare GLP-1 receptor agonists head-to-head: weight loss results, side effects, cost, and which might work best for you.">
    <meta name="ai-content" content="allowed">
    <meta name="ai-topic" content="GLP-1, Ozempic, Mounjaro, Wegovy, weight loss">
    <script type="application/ld+json">
    {
      "@context": "https://schema.org",
      "@graph": [
        {
          "@type": ["Article", "MedicalWebPage"],
          "@id": "https://glp1.md/blog/glp1-medications-compared/#article",
          "headline": "GLP-1 Medications Compared: Ozempic vs Wegovy vs Mounjaro vs Zepbound",
          "description": "Compare GLP-1 receptor agonists head-to-head: weight loss results, side effects, cost, and which might work best for you.",
          "url": "https://glp1.md/blog/glp1-medications-compared/",
          "datePublished": "2026-02-14",
          "dateModified": "2026-02-14",
          "author": {"@type": "Organization", "name": "thrive.md Editorial Team", "url": "https://thrive.md"},
          "publisher": {"@type": "Organization", "name": "glp1.md", "url": "https://glp1.md"},
          "isPartOf": {"@id": "https://glp1.md/#website"},
          "mainEntityOfPage": {"@id": "https://glp1.md/blog/glp1-medications-compared/#article"},
          "wordCount": "662",
          "lastReviewed": "2026-02-14",
          "reviewedBy": {"@type": "Person", "name": "Dr. Agustin Arrieta", "jobTitle": "MD"}
        },{"@type":"FAQPage","mainEntity":[{"@type": "Question", "name": "Is Ozempic the same as Wegovy?", "acceptedAnswer": {"@type": "Answer", "text": "They contain the same active ingredient (semaglutide) but at different doses and with different FDA approvals. Ozempic (up to 2mg) is approved for type 2 diabetes. Wegovy (2.4mg) is approved for chronic weight management. The higher dose in Wegovy is optimized for weight loss rather than glucose control."}}, {"@type": "Question", "name": "Which GLP-1 causes the most weight loss?", "acceptedAnswer": {"@type": "Answer", "text": "Tirzepatide (Mounjaro/Zepbound) at the highest dose produced ~22.5% body weight loss in clinical trials, compared to ~15% for semaglutide (Wegovy). However, individual results vary significantly, and some people respond better to semaglutide than tirzepatide."}}, {"@type": "Question", "name": "Do you gain weight back when you stop GLP-1 medications?", "acceptedAnswer": {"@type": "Answer", "text": "Studies show that most weight returns within 1-2 years of stopping treatment. The STEP 1 extension trial found that participants regained two-thirds of lost weight after discontinuing semaglutide. This suggests GLP-1 medications may need to be taken long-term \u2014 similar to blood pressure or cholesterol medication."}}, {"@type": "Question", "name": "Can you take GLP-1 medications without being diabetic?", "acceptedAnswer": {"@type": "Answer", "text": "Yes. Wegovy and Zepbound are specifically FDA-approved for chronic weight management in adults with BMI \u226530 (or \u226527 with a weight-related comorbidity) regardless of diabetes status. Ozempic and Mounjaro are approved only for diabetes but are frequently prescribed off-label for weight loss."}}]}
      ]
    }
    </script>
    <link rel="icon" type="image/svg+xml" href="data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 32 32'%3E%3Ctext x='16' y='24' font-family='-apple-system,system-ui,sans-serif' font-weight='800' font-size='16' fill='%230d9488' text-anchor='middle' letter-spacing='-0.5'%3E.md%3C/text%3E%3C/svg%3E">
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link href="https://fonts.googleapis.com/css2?family=Source+Serif+4:wght@400;500;600;700&family=Inter:wght@400;500;600&display=swap" rel="stylesheet">
    <style>
        :root {
            --bg-primary: #ffffff;
            --bg-secondary: #f8fafc;
            --text-primary: #0f172a;
            --text-secondary: #475569;
            --text-muted: #94a3b8;
            --accent: #0d9488;
            --accent-dark: #0f766e;
            --border: #e2e8f0;
            --font-display: 'Source Serif 4', Georgia, serif;
            --font-body: 'Inter', -apple-system, sans-serif;
        }
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body { font-family: var(--font-body); background: #fafaf9; color: var(--text-primary); line-height: 1.7; font-size: 16px; }
        a { color: var(--accent); text-decoration: none; }
        a:hover { color: var(--accent-dark); text-decoration: underline; }

        /* Header */
        .site-header { border-bottom: 1px solid var(--border); padding: 1rem 0; background: #fff; }
        .site-header .container { display: flex; align-items: center; justify-content: space-between; }
        .site-logo { font-family: var(--font-display); font-weight: 700; font-size: 1.25rem; color: var(--accent); }
        .site-nav a { margin-left: 1.5rem; color: var(--text-secondary); font-size: 0.9rem; }

        .container { max-width: 720px; margin: 0 auto; padding: 0 1.5rem; }
        .container-wide { max-width: 1080px; margin: 0 auto; padding: 0 1.5rem; }

        /* Article */
        .article-header { padding: 3rem 0 2rem; }
        .article-header h1 { font-family: var(--font-display); font-size: 2.25rem; line-height: 1.25; font-weight: 700; margin-bottom: 1rem; }
        .article-meta { color: var(--text-muted); font-size: 0.875rem; display: flex; gap: 1.5rem; flex-wrap: wrap; }
        .article-meta time, .article-meta .reading-time { display: flex; align-items: center; gap: 0.35rem; }

        /* TOC */
        .toc { background: var(--bg-secondary); border: 1px solid var(--border); border-radius: 8px; padding: 1.25rem 1.5rem; margin-bottom: 2rem; }
        .toc-title { font-weight: 600; font-size: 0.9rem; margin-bottom: 0.75rem; color: var(--text-primary); }
        .toc ol { padding-left: 1.25rem; }
        .toc li { margin-bottom: 0.35rem; font-size: 0.9rem; }
        .toc a { color: var(--text-secondary); }

        /* Content */
        .article-body { padding-bottom: 2rem; }
        .article-body h2 { font-family: var(--font-display); font-size: 1.5rem; font-weight: 600; margin: 2rem 0 1rem; padding-top: 1rem; border-top: 1px solid var(--border); }
        .article-body h3 { font-size: 1.2rem; font-weight: 600; margin: 1.5rem 0 0.75rem; }
        .article-body p { margin-bottom: 1.25rem; }
        .article-body ul, .article-body ol { margin-bottom: 1.25rem; padding-left: 1.5rem; }
        .article-body li { margin-bottom: 0.5rem; }
        .article-body blockquote { border-left: 3px solid var(--accent); padding: 0.75rem 1rem; background: var(--bg-secondary); margin-bottom: 1.25rem; font-style: italic; color: var(--text-secondary); }
        .article-body .source-cite { font-size: 0.8rem; color: var(--text-muted); }
        .article-body .source-cite a { color: var(--accent); }

        /* FAQ */
        .faq-section { background: var(--bg-secondary); border: 1px solid var(--border); border-radius: 8px; padding: 2rem; margin: 2rem 0; }
        .faq-section h2 { border: none; margin-top: 0; padding-top: 0; }
        .faq-item { margin-bottom: 1.5rem; }
        .faq-item:last-child { margin-bottom: 0; }
        .faq-item h3 { font-size: 1.05rem; margin-bottom: 0.5rem; color: var(--accent-dark); }
        .faq-item p { color: var(--text-secondary); font-size: 0.95rem; }

        /* Share */
        .share-bar { display: flex; gap: 0.75rem; margin: 2rem 0; padding: 1.5rem 0; border-top: 1px solid var(--border); border-bottom: 1px solid var(--border); align-items: center; }
        .share-bar span { font-size: 0.875rem; color: var(--text-muted); }
        .share-btn { display: inline-flex; align-items: center; gap: 0.4rem; padding: 0.5rem 1rem; border-radius: 6px; font-size: 0.85rem; font-weight: 500; border: 1px solid var(--border); color: var(--text-secondary); background: #fff; cursor: pointer; transition: all 0.2s; }
        .share-btn:hover { border-color: var(--accent); color: var(--accent); text-decoration: none; }

        /* Related */
        .related-posts { margin: 2rem 0; }
        .related-posts h2 { font-family: var(--font-display); font-size: 1.3rem; margin-bottom: 1rem; border: none; padding: 0; }
        .related-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(220px, 1fr)); gap: 1rem; }
        .related-card { border: 1px solid var(--border); border-radius: 8px; padding: 1.25rem; background: #fff; transition: border-color 0.2s; }
        .related-card:hover { border-color: var(--accent); }
        .related-card h3 { font-size: 0.95rem; margin-bottom: 0.5rem; }
        .related-card p { font-size: 0.8rem; color: var(--text-muted); }

        /* Cross-links */
        .cross-links { margin: 2rem 0; padding: 1.5rem; background: var(--bg-secondary); border-radius: 8px; }
        .cross-links h3 { font-size: 0.95rem; margin-bottom: 0.75rem; color: var(--text-secondary); }
        .cross-links-list { display: flex; flex-wrap: wrap; gap: 0.5rem; }
        .cross-links-list a { padding: 0.35rem 0.75rem; border: 1px solid var(--border); border-radius: 20px; font-size: 0.8rem; color: var(--text-secondary); background: #fff; }
        .cross-links-list a:hover { border-color: var(--accent); color: var(--accent); text-decoration: none; }

        /* Disclaimer */
        .disclaimer { margin: 2rem 0; padding: 1.25rem; background: #fefce8; border: 1px solid #fde68a; border-radius: 8px; font-size: 0.8rem; color: #92400e; line-height: 1.6; }

        /* Footer */
        .site-footer { border-top: 1px solid var(--border); padding: 2rem 0; margin-top: 2rem; text-align: center; }
        .footer-links { display: flex; flex-wrap: wrap; justify-content: center; gap: 1rem; margin-bottom: 1rem; }
        .footer-links a { font-size: 0.8rem; color: var(--text-muted); }
        .footer-copy { font-size: 0.75rem; color: var(--text-muted); }

        @media (max-width: 640px) {
            .article-header h1 { font-size: 1.75rem; }
            .related-grid { grid-template-columns: 1fr; }
        }
    
        /* Medical Reviewer Badge */
        .medical-reviewer { display: flex; align-items: center; gap: 0.4rem; margin-top: 0.75rem; padding: 0.5rem 0.75rem; background: #f0fdfa; border: 1px solid #ccfbf1; border-radius: 6px; font-size: 0.8rem; color: #0f766e; width: fit-content; }
        .medical-reviewer svg { flex-shrink: 0; }
        .medical-disclaimer { font-size: 0.75rem; color: var(--text-muted, #94a3b8); margin-top: 2rem; padding-top: 1rem; border-top: 1px solid var(--border, #e2e8f0); }
    </style>

    <script type="application/ld+json">
    {
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [
    {
      "@type": "ListItem",
      "position": 1,
      "name": "glp1.md",
      "item": "https://glp1.md/"
    },
    {
      "@type": "ListItem",
      "position": 2,
      "name": "Blog",
      "item": "https://glp1.md/blog/"
    },
    {
      "@type": "ListItem",
      "position": 3,
      "name": "GLP-1 Medications Compared: Ozempic vs Wegovy vs Mounjaro vs Zepbound"
    }
  ]
}
    </script>
</head>
<body>
    <header class="site-header">
        <div class="container-wide">
            <a href="https://glp1.md/" class="site-logo">glp1.md</a>
            <nav class="site-nav">
                <a href="https://glp1.md/">Home</a>
                <a href="https://glp1.md/blog/">Blog</a>
            </nav>
        </div>
    </header>

    <main>
        <article class="container">
            <header class="article-header">
                <h1>GLP-1 Medications Compared: Ozempic vs Wegovy vs Mounjaro vs Zepbound</h1>
                <div class="article-meta">
                    <time datetime="2026-02-14">February 14, 2026</time>
                    <span class="reading-time">3 min read</span>
                    <span>By thrive.md Editorial Team</span>
                </div>
            </header>

            <nav class="toc"><div class="toc-title">Table of Contents</div><ol><li><a href="#how-glp-1-medications-work">How GLP-1 Medications Work</a></li><li><a href="#head-to-head-weight-loss-results">Head-to-Head: Weight Loss Results</a></li><li><a href="#same-drug-different-names">Same Drug, Different Names</a></li><li><a href="#side-effects-compared">Side Effects Compared</a></li><li><a href="#cost-and-insurance">Cost and Insurance</a></li><li><a href="#which-one-should-you-choose">Which One Should You Choose?</a></li></ol></nav>

            <div class="article-body">
                <p>The GLP-1 receptor agonist class has transformed obesity and diabetes treatment, but navigating the options ‚Äî semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda) ‚Äî requires understanding how they compare on what matters: weight loss efficacy, side effects, cost, and availability. The short version: tirzepatide produces the most weight loss in clinical trials, semaglutide has the longest track record, and your insurance formulary may make the decision for you.</p><h2 id="how-glp-1-medications-work">How GLP-1 Medications Work</h2><p>GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally produces after eating. It signals your brain to feel full, slows stomach emptying, and stimulates insulin release. GLP-1 medications are synthetic versions that last much longer than the natural hormone ‚Äî days instead of minutes. They effectively turn down your appetite at the neurological level.</p><p>Tirzepatide (Mounjaro/Zepbound) goes further: it's a dual GIP/GLP-1 receptor agonist, meaning it activates two hormones simultaneously. This dual mechanism appears to explain its superior weight loss results. <a href='https://retatrutide.md'>Retatrutide</a>, currently in trials, adds a third receptor (glucagon), which may push results even further.</p><h2 id="head-to-head-weight-loss-results">Head-to-Head: Weight Loss Results</h2><h3>Semaglutide (Wegovy 2.4mg)</h3><p>The STEP trials showed approximately 15-17% body weight loss over 68 weeks. In the STEP 1 trial, participants lost an average of 14.9% of body weight vs 2.4% with placebo. About one-third of participants lost 20% or more.</p><h3>Tirzepatide (Zepbound 15mg)</h3><p>The SURMOUNT-1 trial demonstrated approximately 22.5% body weight loss at the highest dose over 72 weeks. Over a third of participants on the 15mg dose lost 25% or more body weight ‚Äî approaching results previously seen only with bariatric surgery.</p><h3>Liraglutide (Saxenda)</h3><p>The first GLP-1 approved for weight management, liraglutide produces about 5-8% body weight loss ‚Äî significantly less than newer options. It also requires daily injection rather than weekly. It's largely been superseded by semaglutide and tirzepatide but remains an option when others aren't available.</p><h2 id="same-drug-different-names">Same Drug, Different Names</h2><p>This causes significant confusion. <a href='https://ozempic.md'>Ozempic</a> (semaglutide 0.25-2mg) is FDA-approved for type 2 diabetes. Wegovy (semaglutide 2.4mg) is the same molecule at a higher dose, approved for weight management. <a href='https://mounjaro.md'>Mounjaro</a> (tirzepatide) is approved for diabetes. Zepbound (tirzepatide) is the same molecule approved for weight management. Using Ozempic or Mounjaro "off-label" for weight loss is common but affects insurance coverage.</p><h2 id="side-effects-compared">Side Effects Compared</h2><p>GI side effects dominate all GLP-1 medications: nausea (most common, affecting 30-50% of users initially), vomiting, diarrhea, constipation, and abdominal pain. Most people find these manageable and they tend to diminish over weeks. Slow dose titration (starting low, increasing gradually) significantly reduces side effect severity.</p><p>Tirzepatide and semaglutide have similar GI side effect profiles in trials, though some patients tolerate one better than the other ‚Äî switching between them is common. More serious but rare risks include pancreatitis, gallbladder disease, and thyroid concerns (GLP-1 medications carry a boxed warning about thyroid C-cell tumors based on rodent studies, though human evidence is lacking).</p><p>Managing side effects through dietary adjustments is key ‚Äî <a href='https://calories.md'>smaller, protein-rich meals</a> tend to be better tolerated than large, fatty ones during treatment.</p><h2 id="cost-and-insurance">Cost and Insurance</h2><p>Without insurance, these medications cost $1,000-1,500/month. Insurance coverage varies dramatically: many plans cover them for diabetes but not for weight management. Medicare currently doesn't cover anti-obesity medications (though legislation to change this is pending). Manufacturer savings programs can reduce costs significantly for commercially insured patients.</p><p>The cost barrier is the single biggest access issue. This is a class of medications that works remarkably well but remains unaffordable for many of the people who need them most.</p><h2 id="which-one-should-you-choose">Which One Should You Choose?</h2><p>If your primary goal is maximum weight loss and you have access: tirzepatide (Zepbound) produces the best results in trials. If you have type 2 diabetes and need both glucose control and weight loss: either works, but tirzepatide showed superior A1C reduction. If cost or availability is the constraint: whichever your insurance covers. If you tried one and couldn't tolerate the side effects: switch to the other ‚Äî individual tolerability varies.</p><p>Regular exercise alongside GLP-1 treatment improves outcomes and helps preserve lean mass during weight loss. <a href='https://supplements.md'>Adequate protein intake and nutritional support</a> become especially important during rapid weight loss to prevent muscle loss and nutritional deficiencies.</p>
            </div>

            <div class="faq-section"><h2>Frequently Asked Questions</h2><div class="faq-item"><h3>Is Ozempic the same as Wegovy?</h3><p>They contain the same active ingredient (semaglutide) but at different doses and with different FDA approvals. Ozempic (up to 2mg) is approved for type 2 diabetes. Wegovy (2.4mg) is approved for chronic weight management. The higher dose in Wegovy is optimized for weight loss rather than glucose control.</p></div><div class="faq-item"><h3>Which GLP-1 causes the most weight loss?</h3><p>Tirzepatide (Mounjaro/Zepbound) at the highest dose produced ~22.5% body weight loss in clinical trials, compared to ~15% for semaglutide (Wegovy). However, individual results vary significantly, and some people respond better to semaglutide than tirzepatide.</p></div><div class="faq-item"><h3>Do you gain weight back when you stop GLP-1 medications?</h3><p>Studies show that most weight returns within 1-2 years of stopping treatment. The STEP 1 extension trial found that participants regained two-thirds of lost weight after discontinuing semaglutide. This suggests GLP-1 medications may need to be taken long-term ‚Äî similar to blood pressure or cholesterol medication.</p></div><div class="faq-item"><h3>Can you take GLP-1 medications without being diabetic?</h3><p>Yes. Wegovy and Zepbound are specifically FDA-approved for chronic weight management in adults with BMI ‚â•30 (or ‚â•27 with a weight-related comorbidity) regardless of diabetes status. Ozempic and Mounjaro are approved only for diabetes but are frequently prescribed off-label for weight loss.</p></div></div>

            <div class="share-bar">
                <span>Share:</span>
                <a class="share-btn" href="https://twitter.com/intent/tweet?text=GLP-1%20Medications%20Compared%3A%20Ozempic%20vs%20Wegovy%20vs%20Mounjaro%20vs%20Zepbound&url=https://glp1.md/blog/glp1-medications-compared/" target="_blank" rel="noopener">ùïè Twitter</a>
                <a class="share-btn" href="https://www.linkedin.com/sharing/share-offsite/?url=https://glp1.md/blog/glp1-medications-compared/" target="_blank" rel="noopener">LinkedIn</a>
            </div>

            

            

            
    <div class="related-articles" style="margin: 2.5rem 0; padding: 1.5rem; background: #f8fafc; border-radius: 10px; border: 1px solid #e2e8f0;">
        <h3 style="font-family: 'Source Serif 4', Georgia, serif; font-size: 1.15rem; margin-bottom: 1rem; color: #0f172a;">Related Articles</h3>
        <div style="display: grid; gap: 0.75rem;">
            <a href="https://glp1.md/blog/lifestyle-changes-with-glp1.html" style="display: block; padding: 0.75rem; background: white; border-radius: 8px; border: 1px solid #e2e8f0; color: #0f172a; text-decoration: none; transition: border-color 0.2s;">
                <span style="font-weight: 500;">Lifestyle Changes With GLP-1 Medications: Diet, Exercise, and Long-Term Success</span>
                <span style="display: block; font-size: 0.85rem; color: #64748b; margin-top: 0.25rem;">Evidence-based guide to diet, exercise, and lifestyle modifications while taking GLP-1 medications. </span>
            </a>
            <a href="https://glp1.md/blog/glp1-weight-loss-results.html" style="display: block; padding: 0.75rem; background: white; border-radius: 8px; border: 1px solid #e2e8f0; color: #0f172a; text-decoration: none; transition: border-color 0.2s;">
                <span style="font-weight: 500;">GLP-1 Weight Loss Results: What Clinical Trials Actually Show</span>
                <span style="display: block; font-size: 0.85rem; color: #64748b; margin-top: 0.25rem;">Real weight loss data from STEP, SURMOUNT, and SELECT trials for semaglutide and tirzepatide. Averag</span>
            </a>
            <a href="https://glp1.md/blog/how-glp1-agonists-work.html" style="display: block; padding: 0.75rem; background: white; border-radius: 8px; border: 1px solid #e2e8f0; color: #0f172a; text-decoration: none; transition: border-color 0.2s;">
                <span style="font-weight: 500;">How GLP-1 Agonists Work: Mechanism of Action Explained</span>
                <span style="display: block; font-size: 0.85rem; color: #64748b; margin-top: 0.25rem;">A detailed explanation of how GLP-1 receptor agonists work in the body, from incretin signaling to a</span>
            </a>
        </div>
        <div style="margin-top: 1rem; padding-top: 1rem; border-top: 1px solid #e2e8f0;">
            <p style="font-size: 0.85rem; color: #64748b; margin-bottom: 0.5rem;">From the thrive.md network:</p>
            <div style="display: flex; flex-wrap: wrap; gap: 0.5rem;">
                <a href="https://ozempic.md" style="padding: 0.35rem 0.75rem; border: 1px solid #e2e8f0; border-radius: 20px; font-size: 0.8rem; color: #475569; background: white; text-decoration: none;">Ozempic Guide</a>
                <a href="https://mounjaro.md" style="padding: 0.35rem 0.75rem; border: 1px solid #e2e8f0; border-radius: 20px; font-size: 0.8rem; color: #475569; background: white; text-decoration: none;">Mounjaro Guide</a>
                <a href="https://thrive.md" style="padding: 0.35rem 0.75rem; border: 1px solid #e2e8f0; border-radius: 20px; font-size: 0.8rem; color: #475569; background: white; text-decoration: none;">thrive.md Health Network</a>
            </div>
        </div>
    </div>

            <div class="disclaimer">
                <strong>Medical Disclaimer:</strong> This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Never disregard professional medical advice or delay seeking it because of something you read on this site. If you are in crisis, call 988 (Suicide &amp; Crisis Lifeline) or go to your nearest emergency room.
            </div>
        </article>
    </main>

    <div class="email-capture" style="background: linear-gradient(135deg, #f0fdfa 0%, #f8fafc 100%); border: 1px solid #ccfbf1; border-radius: 12px; padding: 2rem; margin: 2rem 0; text-align: center;">
        <p style="font-family: 'Source Serif 4', Georgia, serif; font-size: 1.2rem; font-weight: 600; color: #0f172a; margin-bottom: 0.25rem;">Get evidence-based health updates</p>
        <p style="color: #64748b; font-size: 0.9rem; margin-bottom: 1rem;">No spam. Unsubscribe anytime.</p>
        <form class="email-form" style="display: flex; gap: 0.5rem; max-width: 420px; margin: 0 auto; flex-wrap: wrap; justify-content: center;" onsubmit="submitEmail(event)">
            <input type="email" name="email" placeholder="you@example.com" required style="flex: 1; min-width: 200px; padding: 0.6rem 1rem; border: 1px solid #d1d5db; border-radius: 8px; font-size: 0.95rem; outline: none;">
            <input type="hidden" name="source" value="glp1.md">
            <button type="submit" style="padding: 0.6rem 1.5rem; background: #0d9488; color: white; border: none; border-radius: 8px; font-size: 0.95rem; font-weight: 500; cursor: pointer;">Subscribe</button>
        </form>
        <p class="email-success" style="display: none; color: #0d9488; margin-top: 0.75rem; font-weight: 500;">‚úì You're in! Check your inbox.</p>
    </div>
    <script>
    function submitEmail(e) {
        e.preventDefault();
        const form = e.target;
        const data = new FormData(form);
        fetch('https://script.google.com/macros/s/AKfycbwUqO3zauyG_tuCZk0NALIDybayC7JhTbSm7RcQhivv6Lq0XCrQ8YgopTFqXjMSwt72/exec', {
            method: 'POST', body: data, mode: 'no-cors'
        }).then(() => {
            form.style.display = 'none';
            form.parentElement.querySelector('.email-success').style.display = 'block';
        });
    }
    </script>


    <footer class="site-footer">
        <div class="container-wide">
            <div class="footer-links">
                <a href="/about.html">About &amp; Editorial Policy</a>
                <a href="https://thrive.md">thrive.md</a>
                <a href="https://anxiety.md">anxiety.md</a>
                <a href="https://depression.md">depression.md</a>
                <a href="https://ptsd.md">ptsd.md</a>
                <a href="https://bipolar.md">bipolar.md</a>
                <a href="https://ocd.md">ocd.md</a>
                <a href="https://insomnia.md">insomnia.md</a>
                <a href="https://ozempic.md">ozempic.md</a>
                <a href="https://hypertension.md">hypertension.md</a>
            </div>
            <p class="footer-copy">&copy; 2026 glp1.md ‚Äî Part of the <a href="https://thrive.md">thrive.md</a> health network</p>
        </div>
    </footer>

    <script>
    // GA4 engagement tracking
    let scrollMax = 0;
    window.addEventListener('scroll', function() {
        const pct = Math.round((window.scrollY / (document.body.scrollHeight - window.innerHeight)) * 100);
        if (pct > scrollMax) {
            scrollMax = pct;
            if ([25, 50, 75, 100].includes(pct)) {
                gtag('event', 'scroll_depth', { percent: pct, page: location.pathname });
            }
        }
    });
    // Time on page
    const startTime = Date.now();
    window.addEventListener('beforeunload', function() {
        const seconds = Math.round((Date.now() - startTime) / 1000);
        gtag('event', 'time_on_page', { seconds: seconds, page: location.pathname });
    });
    </script>
</body>
</html>
